Lecanemab in Early Alzheimer’s Disease

H. van Dyck, Christopher; J. Swanson, Chad; Aisen, Paul; J. Bateman, Randall; Chen, Christopher; Gee, Michelle; Kanekiyo, Michio; Li, David; Reyderman, Larisa; Cohen, Sharon; Froelich, Lutz; Katayama, Sadao; Sabbagh, Marwan; Vellas, Bruno; Watson, David; Dhadda, Shobha; C. Irizarry, Michael; D. Kramer, Lynn; Iwatsubo, Takeshi

doi:10.1056/nejmoa2212948

Public

Lecanemab in Early Alzheimer’s Disease

Published in New England Journal of Medicine • Nov 30, 2022

Authors:

Christopher H. van Dyck

Chad J. Swanson

Paul Aisen

Abstract

BACKGROUND: The accumulation of soluble and insoluble aggregated amyloid-beta (Aβ) may initiate or potentiate pathologic processes in Alzheimer's disease. Lecanemab, a humanized IgG1 monoclonal antibody that binds with high affinity to Aβ soluble protofibrils, is being tested in persons with early A...

Subject

Disease

Alzheimer's disease

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!